Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$70.57M$70.57M+81,958.1% vs Q3 2024 Net Income-$34.60M-$34.60MN/M vs Q3 2024 EPS, diluted—
Operating Income-$40,013,000N/M Operating Cash Flowderived-$84,611,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$84,738,000N/M Margins · derivedOperating margin-56.7%+97013.1 pt vs Q3 2024
Net margin-49.0%+89124.2 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 5, 2025 · 36 d after period end